Plus Therapeutics Gains $15 Million to Propel Cancer Research
Plus Therapeutics Advances with New Funding for CNS Cancer Therapies
Plus Therapeutics, Inc. (Nasdaq: PSTV), a clinical-stage pharmaceutical company, has recently announced a significant financial development that could catalyze the advancement of its innovative CNS cancer therapies. This comes as they have successfully secured a private placement that is expected to generate approximately $15 million in gross proceeds.
Marc H. Hedrick, M.D., President and CEO of Plus Therapeutics, expressed enthusiasm regarding the financing. He emphasized that this funding would not only enhance their existing support from grants but also empower the company to swiftly progress its treatment strategies for central nervous system cancers. The company aims to meet critical milestones and generate long-term value for its shareholders.
The Details of the Offering
The private placement involves the sale of 28,042,140 common units, or pre-funded units, each comprising a share of common stock or a pre-funded warrant, along with Series A and Series B warrants. The common units are priced at $0.66 each, with pre-funded units available at a slightly lower price of $0.659. This reduction accounts for a minimal exercise price attributed to the pre-funded warrants.
Of the total units, 22,727,270 are being issued for new capital subscriptions, while 5,314,870 units are exchanged for the cancellation of previously issued convertible promissory notes. Importantly, the pre-funded warrants are immediately exercisable, allowing investors quick access to their shares. The company anticipates utilizing the net proceeds from this placement to settle outstanding promissory notes not involved in the offering, repurchase certain warrants, and address working capital needs.
Plans for Fund Utilization
Plus Therapeutics plans to place the raised funds in escrow, with release contingent on confirmation that the company will not face delisting risks associated with previous Nasdaq hearings. Should confirmation remain unobtained by the end of a specific deadline, the offering will conclude, ensuring that funds revert to the original investors. The timeliness and appropriateness of this funding are crucial as the company aims to solidify its operational and developmental foundation.
In addition to the immediate funds raised, the company will benefit from the exchange of approximately $3.2 million in senior convertible debt that was addressed during this placement. This strategic move effectively reduces overall liabilities, further solidifying the company’s financial standing.
Who is Behind the Offering?
D. Boral Capital has been engaged as the Placement Agent for this offering, while Hogan Lovells US LLP provides legal counsel for Plus Therapeutics. Simultaneously, Sichenzia Ross Ference Carmel LLP represents D. Boral Capital, ensuring legal compliance and oversight throughout this financial process.
About Plus Therapeutics
Plus Therapeutics is leading the charge in the realm of targeted treatments for challenging CNS cancers. They are dedicated to enhancing the treatment landscape through innovative therapy approaches combining local beta radiation and targeted delivery methods for improved patient outcomes. Their ongoing commitment is clearly reflected in their development pipeline, spearheaded by notable programs aimed at tackling recurrent glioblastoma and leptomeningeal metastases.
To support these initiatives, Plus Therapeutics has strategically developed partnerships and a robust supply chain aimed at aiding product development and potential commercialization. The company continues to be fueled by an experienced management team and operations located in significant cancer development hubs.
Frequently Asked Questions
1. How much funding did Plus Therapeutics secure with this placement?
Plus Therapeutics secured approximately $15 million in gross proceeds from the private placement.
2. What are the primary uses for the funds raised?
The funds will be used for repaying outstanding promissory notes, repurchasing certain warrants, and general corporate purposes.
3. Who acted as the legal counsel for the offering?
Hogan Lovells US LLP acted as counsel for Plus Therapeutics during this financing process.
4. What types of warrants are included in the offering?
The offering includes Series A and Series B warrants, each allowing purchase of common stock at specified prices.
5. What is the main focus of Plus Therapeutics?
Plus Therapeutics focuses on developing innovative treatments for difficult-to-treat cancers of the central nervous system, aiming to improve patient outcomes.
About The Author
Contact Ryan Hughes privately here. Or send an email with ATTN: Ryan Hughes as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.